5-azacytidine Can Enchance The Cardiomyogenic Differentiation Of Bone Marrow Mesenchymal Stem Cell Coculturing With Neonatal Rat Cardiomyocyte

INTRODUCTION Cellular cardiomyoplasty (CCMP) is an alternative therapy that transplants cells into the heart of end-stage heart failure for regenating myocardium. Fetal cardiomyocytes, skeletal myoblasts, embryonic stem cells, fibroblasts, smooth muscle cells, and hematopoietic stem cells have been transplanted into host myocardium. All reported techniques of CCMP have limitations and shortcomings, and these depend primarily on the type of cell used for transplantation. Ideally, cells for use in CCMP should be pluripotent, possess the capacity to differentiate to the desired cell type under appropriate stimuli, have a limited capacity to multiply, and should be capable of functional integration into the host myocardium. The bone marrow mesenchymal stem cells (BMSCs) have many of these characteristics, and as such may be highly suitable for CCMP. Under appropriate stimuli these stem cells are highly plastic and can differentiate into specialized tissues such as myogenic cells, cartilage, osteocytes, adipocytes, and cardiac cells.5-azacytidine(5-Aza) is a cytosine analogue. BMSCs treated with 5-Aza can transdifferentiate into a cardiac phenotype in vitro. At present, some people preconditioned the BMSCs with 5-Aza before cell transplantation for an increased conversion in culture of BMSCs to...